Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL
A new fat-busting drug that is available as a jab or tablet helps patients lose up to a quarter of their body weight, studies suggest.
People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of treatment.
And those taking daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks, the early stage trials found.
Weight loss jabs have been hailed as transformative by NHS leaders.
But tablets could be the next big breakthrough in the nation's fight against obesity as they are likely to appeal to a wider audience who are uncomfortable with injecting themselves.
An estimated 1.5million Britons use weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions.
GPs will be able to dish out fat jabs from next week.
Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body—GLP-1 and the amylin receptor.
In comparison to amycretin, trials pivotal to getting semaglutide—the ingredient behind Ozempic—approved, show it helped users shed up to 15 per cent of their body weight over 68 weeks.
And studies have found rival jab Mounjaro can help obese people lose up to 22.5 per cent of their body weight in 72 weeks.
The new amycretin trial involved 125 adults, who took weekly injections of the drug.
Those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs in improving blood sugar levels.
Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment, according to findings published in medical journal The Lancet.
'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote.
'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.'
The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks.
There were mild to moderate side effects including loss of appetite, nausea and vomiting.
Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months.
The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity.
'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.'
The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US.
It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses.
Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
GLP-1 injections suffered global shortages after celebrity users sparked a surge in popularity and the NHS has warned people against buying them from unauthorised sources.
Professor Sir Stephen Powis, national medical director at NHS England, last week told the NHS ConfedExpo conference in Manchester that weight loss jabs could be doled out as widely as statins if competition in the market brings their price down
The country's top doctor warned obesity costs the NHS £11.4billion every year and described the financial burden as 'unsustainable'.
From Monday, GPs will be able to prescribe the fat jab mounjaro - also known as tirzepatide - for the first time, in what he labelled an 'exciting milestone'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
40 minutes ago
- Daily Mail
How to STOP taking HRT: You're not supposed to take it indefinitely and coming off can be life-changing. Now DR ELLIE CANNON reveals the dangers - and how to know if it's time to quit
It's hard to overstate the revolution that has occurred in menopause treatment over the past decade. In the UK, it is thought that about 13 million women are, at any one time, experiencing the distinctive midlife issues – including low mood, anxiety, hot flushes and difficulty sleeping.
Daily Mail
an hour ago
- Daily Mail
Cheap supplement that could banish painful UTIs praised by patients as 'life changing'... so why won't the NHS endorse it?
For the million or so Britons who suffer urinary tract infections (UTIs) every year, the symptoms are all too familiar: discomfort, rushing to the loo and a burning sensation when peeing. And although antibiotics are routinely prescribed, many patients – more commonly women than men – either find the drugs don't always cure the problem or the infections quickly return. But experts now believe these debilitating infections could, in some cases, be prevented and treated with a dietary supplement costing as little as 50p a day. In her Mail on Sunday column last week, Dr Ellie Cannon wrote that, despite being sceptical about supplements in general, she'd been impressed by patients' experiences with one called D-mannose. In response, dozens of readers sent messages detailing how taking it had dramatically improved their health. Jane Ellaby, 75, from near Sheffield, struggled for years with the bladder infection cystitis – until D-mannose banished her symptoms. She said: 'I've recommended this supplement to several friends who've also had positive results.' Maureen Mathieson, 57, from Ayrshire, has taken D-mannose for five years. She said: 'I regularly suffered from UTIs which made me miserable – despite repeatedly taking antibiotics. A nurse suggested D-mannose and it's been really successful.' And for Elaine Leake, 75, from Durham, up to six bladder infections a year also meant regular antibiotics – until a urologist recommended D-mannose. She said: 'I haven't had a bladder infection since April 2021.' According to Dr Cat Anderson, a GP and specialist in women's health, the benefits can't be overstated. She says: 'People who haven't suffered UTIs tend to underestimate how devastating they can be. At worst, patients can be peeing up to 50 times a day: they don't sleep, they become depressed and run-down, their immune system takes a hit. 'Finding something like D-mannose that actually helps is incredibly valuable.' Each year more than a million Britons, 80 per cent of them women, develop a UTI in either the bladder, urethra (the tube carrying urine out of the bladder) or kidneys. Most are caused by bacteria in the urinary tract – with responsible for up to 90 per cent of cases. D-mannose is a form of sugar molecule found in some fruits and vegetables – and is sold as a dietary supplement, in tablets or powder form. It is not absorbed by the body and is quickly excreted in urine. Experts who back its use believe that, while passing through the urinary tract, the molecule binds to harmful bacteria which are then flushed away before they can cause infection. Dr Anderson says: 'It's a bit like rolling a sticky dough-ball in flour. The bacteria – especially – bind to the D-mannose molecules rather than to bladder cells.' However, scientific research is divided on D-mannose, and it is not prescribed on the NHS. A study earlier this year by the National Institute for Health and Care Research (NIHR) concluded it does not prevent UTIs. But a German study published in 2022 in the journal Antibiotics, found that, in patients with acute cystitis, D-mannose produced 'very good clinical cure rates'. Dr Anderson is confident that more in-depth research will conclusively prove the value of the supplement. She says: 'You have to pump millions into high-grade clinical trials, but UTIs aren't an area like cancer or heart disease that attracts funding. But if these trials were performed, I can guarantee D-mannose would deliver. 'Until then, there's nothing better than experiential evidence – speaking to patients and listening to what they say works.' Ased Ali, a consultant urological surgeon at Pinderfields Hospital in West Yorkshire and also a member of the medical panel for charity Bladder Health UK, says that as D-mannose has a low risk of side effects it should be considered for patients plagued by UTIs. He adds: 'I've seen some very positive results in practice. 'Given its low risk, I think it's reasonable to consider D-mannose as part of a broader approach to UTI prevention.' It's certainly something MoS reader Sue Molt, 75, from Rochdale, would recommend. She wrote: 'Finally I found something that helped my problem – and I've never looked back.'
Times
an hour ago
- Times
A robot surgeon? I'll put my money on that
T hank you for waiting, the robot will see you now. Nine in ten keyhole operations won't need a human surgeon in the room within the next decade, according to the NHS. One in five operations are already carried out by robots, guided remotely, to improve outcomes while cutting costs. Science fiction is becoming surgical fact because robotic-assisted surgery can mean smaller incisions, reduced scarring and quicker recovery. There's no need to take my word for it: Sir Jim Mackey, the chief executive of the NHS, said: 'We are using every tool to ensure patients get the best possible treatment. Expanding the use of new tech, such as robotic surgery, will play a huge part.' Wes Streeting, the health and social care secretary, added: 'I know how important this is. The NHS saved my life from kidney cancer with an operation led by a world-class surgeon being helped by a robot.'
